Argenx
ARGX
#404
Rank
HK$483.14 B
Marketcap
HK$7,769
Share price
-0.55%
Change (1 day)
35.04%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): HK$123.35

According to Argenx 's latest financial reports the company's current EPS (TTM) is HK$124.03. In 2025 the company made an earnings per share (EPS) of HK$165.37 an increase over its 2024 EPS that were of HK$109.20.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$123.35-25.41%
2025HK$165.3751.44%
2024HK$109.20-369.77%
2023-HK$40.48-60.46%
2022-HK$102.3863.33%
2021-HK$62.68-40.37%
2020-HK$105.12183.47%
2019-HK$37.08123.09%
2018-HK$16.6254.93%
2017-HK$10.7314.07%
2016-HK$9.4113.05%
2015-HK$8.32-36.34%
2014-HK$13.07209.04%
2013-HK$4.23-33.99%
2012-HK$6.41185.59%
2011-HK$2.24